Efficacy of recombinant versus human derived follicle stimulating hormone on the oocyte and embryo quality in IVF-ICSI cycles: Randomised, controlled, multi-centre trial

References

• Edwards R G, Lobo R, Bouchard P. Time to revolutionize ovarian stimulation. Hum Reprod 1996; 11: 917–919
   PubMed Web of Science ®Google Scholar
• Gerris J M. Single embryo transfer and IVF/ICSI outcome: a balanced appraisal. Hum Reprod Update Mar-Apr, 2005; 11: 105–121
   PubMed Web of Science ®Google Scholar
• Fleming R, Coutts J R. Induction of multiple follicular development for IVF. Br Med Bull 1990; 46: 596–615
   PubMed Web of Science ®Google Scholar
• Sullivan M W, Stewart-Akers A, Krasnow J S, Berga S L, Zeleznik A J. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinising hormone (LH): a role for LH in the final stages of follicular maturation. J Clin Endocrinol Metab 1999; 84: 228–232
   PubMed Web of Science ®Google Scholar
• Filicori M, Cognigni G E, Taraborrelli S, Spettoli D, Ciampaglia W, Tabarelli De Fatis C, Pocognoli P, Cantelli B, Boschi S. Luteinizing hormone activity in menotrophins optimizes folliculogenesis and treatment in controlled ovarian stimulation. J Clin Endocrinol Metab 2001; 86: 337–343
   PubMed Web of Science ®Google Scholar
• Filicori M, Cognigni G E, Tabarelli C, Pocognoli P, Taraborrelli S, Spettoli D, Ciampaglia W. Stimulation and growth of antral ovarian follicles by selective LH activity administration in women. J Clin Endocrinol Metab 2002; 87: 1156–1161
   PubMed Web of Science ®Google Scholar
• Loumaye E, Engrand P, Shoham Z, Hillier S G, Baird D T. Clinical evidence of an LH ‘ceiling’ effect induced by administration of recombinant human LH during the late follicular phase of stimulation cycles in World Health Organization type I and type II anovulation. Hum Reprod 2003; 18: 314–322
   PubMed Web of Science ®Google Scholar
• Smitz J, Nyboe Andersen A, Devroey P, Arce J-C. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Hum Reprod 2007; 22: 676–687, for the MERIT group
   PubMed Web of Science ®Google Scholar
• Bosch E, Vidal C, Labarta E, Simon C, Remohi J, Pellicer A. Hightly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists – a randomized study. Hum Reprod 2008; 23: 2346–2351
   PubMed Web of Science ®Google Scholar
• Cummins J M, Breen T M, Harison K L, Shaw J M, Wilson L M, Hennessey J F. A formula for scoring human embryo growth rates in in vitro fertilization: its value in predicting pregnancy and in comparison with visual estimates of embryo quality. J In Vitro Fert Embryo Transfer 1986; 3: 284–295
   PubMedGoogle Scholar
• Puissant F, Van Rysselberge M, Barlow P, Deweze J, Leroy F. Embryo scoring as a prognostic tool in IVF treatment. Hum Reprod 1987; 2: 705–708
   PubMed Web of Science ®Google Scholar
• Staessen C, Camus M, Bollen N, Devroey P, Van Steirteghem A C. The relationship between embryo quality and the occurrence of multiple pregnancies. Fertil Steril 1992; 57: 626–630
   PubMed Web of Science ®Google Scholar
• Shulman A, Ben-Nun I, Ghetler Y, Kaneti H, Shilon M, Beyth Y. Relationship between embryo morphology and implantation rate after in vitro fertilization treatment in conception cycles. Fertil Steril 1993; 60: 123–126
   PubMedGoogle Scholar
• Ziebe S, Petersen K, Lindenberg S, Andersen A G, Gabrielsen A, Nyboe Andersen A. Embryo morphology or cleavage stage: how to select the best embryo for transfer after in vitro fertilization. Hum Reprod 1997; 12: 1545–1549
   PubMed Web of Science ®Google Scholar
• Thurin A, Hardarson T, Hausken J, Jablonowska B, Lundin K, Pinborg A, Bergh C. Predictors of ongoing implantation in IVF in a good prognosis group of patients. Hum Reprod 2005; 20: 1876–1880
   PubMed Web of Science ®Google Scholar
• Macklon N S, Fauser B CJM. Mild stimulation in in vitro fertilization. Ann NY Acad Sci 2003; 997: 105–111
   PubMedGoogle Scholar
• Italian Law on Medically Assisted Reproduction (law n. 40/2004). Italian Law of February 19th 2004. Available from: http://www.parlamento.it/leggi/04040l. htm
   Google Scholar
• Loumaye E, Campbell R, Salat-Baroux J. Human follicle stimulating hormone produced by recombinant DNA technology: a review for clinicians. Hum Reprod Update 1995; 1: 188–199
   PubMed Web of Science ®Google Scholar
• Stanger J D, Yovich J L. Reduced in-vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase. Br J Obstet Gynaecol 1985; 92: 385–393
   PubMedGoogle Scholar
• Homburg R, Armar N A, Eshel A, Adams J, Jacobs H S. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. BMJ 1988; 297: 1024–1026
   PubMed Web of Science ®Google Scholar
• Regan L, Owen E J, Jacobs H S. Hypersecretion of luteinising hormone, infertility, and miscarriage. Lancet 1990; 336: 1141–1144
   PubMed Web of Science ®Google Scholar
• Chappel S C, Howles C M. Re-evaluation of the roles of luteinizing hormone and follicle stimulating hormone in the ovulatory process. Hum Reprod 1991; 6: 1206–1212
   PubMed Web of Science ®Google Scholar
• Westergaard L G, Laursen S B, Andersen C Y. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod 2000; 15: 1003–1008
   PubMed Web of Science ®Google Scholar
• Gordon U D, Harrison R F, Fawzy M, Hennelly B, Gordon A C. A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome. Fertil Steril 2001; 75: 324–331
   PubMed Web of Science ®Google Scholar
• Platteau P, Smitz J, Albano C, Sørensen P, Arce J-C, Devroey P. Exogenous luteinizing hormone activity may influence the treatment outcome in in vitro fertilization but not in intracytoplasmic sperm injection cycles. Fertil Steril 2004; 81: 1401–1404
   PubMed Web of Science ®Google Scholar
• Lisi F, Rinaldi L, Fishel S, Caserta D, Lisi R, Campbell A. Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertil Steril 2005; 83: 309–315
   PubMed Web of Science ®Google Scholar
• Macklon N S, Stouffer R L, Giudice L C, Fauser B CJM. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocrine Rev 2006; 27: 170–207
   PubMed Web of Science ®Google Scholar
• Al-Inany H, Aboulghar M, Mansour R, Serour G. Meta-analysis of recombinant versus urinary-derived FSH: an update. Hum Reprod 2003; 18: 305–313
   PubMed Web of Science ®Google Scholar
• Bayram N, van Wely M, van der Veen F. Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovarian syndrome. Cochrane Database Syst Rev 2001, 2, CD002121
   PubMedGoogle Scholar
• Balen A, Platteau P, Andersen A N, Devroey P, Helmgaard L, Arce J-C. Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non-inferiority trial. Hum Reprod 2007; 22: 1816–1823
   PubMed Web of Science ®Google Scholar
• Demirol A, Gurgan T. Comparison of different gonadotrophin preparations in intrauterine insemination cycles for the treatment of unexplained infertility: a prospective, randomized study. Hum Reprod 2007; 22: 97–100
   PubMedGoogle Scholar
• Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt P M, van Wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod 2008; 23: 310–315
   PubMed Web of Science ®Google Scholar
• Platteau P, Nyboe Andersen A, Loft A, Smitz J, Danglas P, Devroey P. Highly purified hMG versus recombinant FSH for ovarian stimulation in IVF cycles. Reprod Biomed Online 2008; 17: 190–198
   PubMedGoogle Scholar
• Andersen A N, Devroey P, Arce J-C. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF; a randomized assessor-blind controlled trial. Hum Reprod 2006; 21: 3217–3227, for the MERIT Group
   PubMed Web of Science ®Google Scholar
• Hompes P G, Broekmans F J, Hoozemans D A, Schats R. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients. Fertil Steril 2008; 89: 1685–1693, for the FIRM Group
   PubMed Web of Science ®Google Scholar
• Mohamed M A, Sbracia M, Pacchiarotti A, Micara G, Linari A, Tranquilli D, Esponola S M, Aragona C. Urinary follicle-stimulating hormone (FSH) is more effective than recombinant FSH in older women in a controlled randomized study. Fertil Steril 2006; 85: 1398–1403
   PubMed Web of Science ®Google Scholar
• Selman H A, De Santo M, Sterzik K, Coccia E, El-Danasouri I. Effect of highly purified urinary follicle stimulating hormone on oocyte and embryo quality. Fertil Steril 2002; 78: 1061–1067
   PubMed Web of Science ®Google Scholar
• Pacchiarotti A, Aragona C, Gaglione R, Selman H. Efficacy of a combined protocol of urinary and recombinant follicle-stimulating hormone used for ovarian stimulation of patients undergoing ICSI cycle. J Assist Reprod Genet 2007; 24: 400–405
   PubMed Web of Science ®Google Scholar
• Anserini P, Costa M, Remorgida V, Venturini P L. A prospective, randomized, controlled clinical study of a new subcutaneous, purified, urinary FSH preparation for controlled ovarian hyperstimulation in in vitro fertilization. Gynecol Endocrinol 2000; 14: 75–80
   PubMed Web of Science ®Google Scholar
• Gerli S, Perino M, Abate A, Costabile L, Gholami H, Vitiello L. Ovarian stimulation using a new highly purified urinary FSH: a prospective randomized clinical study. Clin Exp Obstet & Gyn 1999; 26: 93–94
   PubMedGoogle Scholar
• Gerli S. Ovulation induction with urinary FSH or recombinant FSH in polycystic ovarian syndrome patients: a prospective randomized analysis of cost-effectiveness. RBM Online 2004; 9: 494–499
   Google Scholar
• Silverberg K, Daya S, Auray J P, Duru G, Ledger W, Wikland M, Bouzayen R, O'Brien M, Falk B, Beresniak A. Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection programs in the United States. Fertil Steril 2002; 77: 107–113
   PubMed Web of Science ®Google Scholar
• Hatoum H T, Keye W R, Marrs R P, Walton S M, Marshall D C. A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data. Fertil Steril 2005; 83: 804–807
   PubMed Web of Science ®Google Scholar
• Gerli S, Bini V, Di Renzo G C. Cost-effectiveness of recombinant follicle-stimulating hormone (FSH) versushuman FSH in intrauterine insemination cycles: a statistical model-derived analysis. Gynecol Endocrinol 2008; 24: 18–23
   PubMed Web of Science ®Google Scholar